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Abstract The lymphatic system transports interstitial
fluid and macromolecules from tissues back to the blood
circulation, and plays an important role in the immune
response by directing the traffic of lymphocytes and
antigen-presenting cells. The lymphatic system also
constitutes one of the most important pathways of tumor
dissemination. In many human cancers, increased expres-
sion of vascular endothelial growth factor-C (VEGF-C) is
correlated with regional lymph node metastases. Exper-
imental studies using transgenic mice overexpressing
VEGF-C or xenotransplantation of VEGF-C-expressing
tumor cells into immunodeficient mice have demonstrated
a role for VEGF-C in tumor lymphangiogenesis and the
subsequent formation of lymph node metastases. How-
ever, there is at present little evidence for lymphangio-
genesis in human tumors and the relative importance of
preexisting vs. newly formed lymphatics for metastasis in
humans remains to be determined. Nonetheless, the
striking correlation between the levels of VEGF-C in
primary human tumors and lymph node metastases
predicts its importance in cancer spread. Aside from
promoting lymphangiogenesis, VEGF-C may also acti-
vate lymphatics to promote tumor cell chemotaxis,
lymphatic intravasation and hence tumor cell dissemina-
tion.
Keywords Cancer · Metastasis · Lymphangiogenesis ·
VEGF-C · VEGFR-3
Introduction
The lymphatic system collects extravasated fluid, macro-
molecules and cells of the immune system within tissues
and returns them to the blood circulation. This extensive
drainage network is lined by a continuous layer of
endothelial cells and is interspaced by lymph nodes. It
begins in the tissues as a series of blind-ending capillaries
which drain into collecting vessels that return lymph to
the systemic blood circulation via the thoracic duct. When
lymphatic circulation is compromised, lymphedema en-
sues. In addition to providing a means for interstitial fluid
return to the circulation, the lymphatic system plays an
important role in the immune response by directing
lymphocytes and antigen presenting cells to lymph nodes.
With regard to pathology, the lymphatic system consti-
tutes one of the most important pathways for tumor cell
dissemination (Pepper 2001; Stacker et al. 2002; Swartz
and Skobe 2001).
Because the lymphatic system is optimally suited for
the entry and transport of cells (e.g., immune cells) (Witte
et al. 1997), it also has many advantages over the blood
circulation as a transport route for metastasizing tumor
cells. The smallest lymphatic vessels are much larger than
blood capillaries, and flow velocities are orders of
magnitude lower. Lymph is nearly identical to interstitial
fluid and promotes cell viability. In contrast, tumor cells
in the bloodstream experience serum toxicity, high shear
stresses and mechanical deformation, leading to an
extremely low success rate for metastasis formation
(Liotta et al. 1991; Weiss and Schmid-Schonbein 1989).
Metastasis via lymphatics might therefore promote sur-
vival of disseminating tumor cells and consequently
increase their metastatic efficiency. Nearly all investiga-
tions of the mechanisms of metastasis, such as intrava-
sation, survival, and extravasation, have focused on tumor
cell behavior in the bloodstream (Liotta et al. 1991; Zetter
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1993). There is therefore an urgent need to understand
how tumor cells interact with lymphatics and to develop a
paradigm for lymphatic metastasis analogous to that of
hematogenous metastasis (Swartz and Skobe 2001).
Despite the longstanding recognition of the involve-
ment of the lymphatic system in many clinical settings,
formal experimental demonstration of its role (including
lymphangiogenesis) in the pathogenesis of lymphedema
or tumor cell dissemination has until recently been
lacking. This was mainly due to the lack of lymphatic-
specific markers as well as identification of lymphangio-
genic growth factors and their receptors. However, much
progress has been made in these areas in the past decade.
It is now also possible to culture pure populations of
blood and lymphatic vascular endothelial cells using the
molecular tools which have become available. In this
respect, one can truly speak of a renaissance in the field of
lymphatic endothelial biology and pathophysiology.
Lymphatic endothelial cell biology: a renaissance
Lymphatic endothelial cell markers
Until the discovery of specific markers, lymphatic vessels
were identified indirectly by lymphangiography, which is
based on the ability of lymphatic capillaries to take up
dyes and high-molecular weight molecules from the
interstitium. Most commonly used are vital dyes—Evans
blue, trypan blue and patent blue—and, more recently,
fluorescently labeled tracers. The absence of basement
membrane components such as laminin, collagen IV and
collagen XVIII, the lack of PAL-E staining of CD31-
positive endothelial cells, and 5’-nucleotidase activity
have also been considered lymphatic endothelial-specific
criteria (Sleeman et al. 2001).
In the past few years, several positive markers specific
for lymphatic endothelium have been discovered. These
include vascular endothelial growth factor receptor-3
(VEGFR-3), which is predominantly expressed by lym-
phatic endothelial cells in normal adult tissues, but can
also be expressed by blood vascular endothelial cells in
tumors or during wound healing. Other transmembrane
proteins such as LYVE-1 (Banerji et al. 1999) and
podoplanin (Breiteneder-Geleff et al. 1999) and a tran-
scription factor Prox-1 (Wigle and Oliver 1999) have
been shown to be reliable in distinguishing lymphatic
from blood endothelium, although none is strictly endo-
thelial-specific (Sleeman et al. 2001).
Lymphangiogenic growth factors
Two lymphangiogenic factors, which are members of the
VEGF family, have been identified to date: VEGF-C and
VEGF-D. Other molecules which play an important role
in the development of the lymphatic system include
angiopoietin-2 (Gale et al. 2002), neuropilin-2 (Yuan et
al. 2002) and Prox-1 (Wigle and Oliver 1999).
The VEGF family comprises several secreted glyco-
proteins that play a prominent role in the formation of
blood and lymphatic vessels. The mammalian VEGF
family consists of VEGFs-A, -B, -C and -D as well as
placental growh factor (PlGF). VEGF signaling in
endothelial cells occurs through three tyrosine kinase
receptors (VEGFRs): VEGFRs-1, -2 and -3. VEGFR-1
binds to VEGFs-A and -B and PlGF, VEGFR-2 binds
VEGFs-A, -C and -D, whereas VEGFR-3 binds only
VEGFs-C and -D. In adult tissues VEGFRs-1 and -2 are
predominantly expressed by blood vascular endothelial
cells and signal to promote cell proliferation, migration,
and angiogenesis. VEGFR-2 has also been detected on
lymphatic endothelium in vivo (Nagy et al. 2002; Saaristo
et al. 2002) and in vitro (Kriehuber et al. 2001; Makinen
et al. 2001b; Podgrabinska et al. 2002), yet its role in
lymphangiogenesis is less clear. VEGFR-3, which is
widely expressed in the early embryonic vasculature,
becomes restricted to lymphatic endothelial cells in the
later stages of embryogenesis and in the adult (Dumont et
al. 1998) and is also expressed in some fenestrated blood
vessels (Partanen et al. 2000). VEGFs-C and -D are
secreted as homodimers that undergo extensive proteo-
lytic processing of their N- and C-terminal domains
following secretion (Joukov et al. 1997; Stacker et al.
1999). Processing of VEGFs-C and -D alters their
receptor binding affinities, thereby modulating the bio-
logical effects of these growth factors. The secreted 31-
kDa form of VEGF-C/-D predominantly activates VEG-
FR-3, whereas the mature, fully processed 21-kDa form
activates both VEGFRs-2 and -3.
VEGFs-C and -D have the dual capacity to induce
lymphangiogenesis and angiogenesis, as demonstrated in
a number of experimental systems including the chick
chorioallantoic membrane (CAM), the rabbit cornea assay
and transgenic mice (Table 1). Application of recombi-
nant VEGF-C protein to the differentiated avian CAM or
the mouse cornea (Kubo et al. 2002; Oh et al. 1997) as
well as application of tumor cells onto the differentiated
avian CAM (Papoutsi et al. 2000, 2001) (Table 5) leads to
lymphatic endothelial proliferation and the formation of
new lymphatic capillaries. Local transfer of naked
plasmid DNA encoding human VEGF-C in two animal
models of secondary lymphedema (one in the rabbit ear
and one in the mouse tail) promoted selective prolifera-
tion of functional lymphatics associated with increased
lymphatic drainage and decreased skin thickening (Yoon
et al. 2003). Similar effects were obtained by adminis-
tration of a single dose of recombinant VEGF-C in the
same model of acquired lymphedema in the rabbit ear
(Szuba et al. 2002). Viral gene delivery of fully processed
VEGF-D in rat skin induced a significant lymphangio-
genic effect together with a (less robust) angiogenic
response, whereas viral gene delivery of VEGF-A in the
same setting only induced angiogenesis (Byzova et al.
2002). In transgenic mice expressing VEGF-D or VEGF-
C, or a VEGF-C mutant (VEGF-C-156S) that binds
VEGFR-3 but not VEGFR-2, VEGFR-3 signaling was
shown to be sufficient to mediate selective lymphangio-
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genesis without affecting angiogenesis (Jeltsch et al.
1997; Veikkola et al. 2001). During early embryogenesis,
lack of VEGFR-3 in VEGFR-3-null mice affects neither
vasculogenesis nor angiogenesis. Instead, remodeling and
maturation of blood vessels are impaired, leading to
embryonic death at day 9.5, well before the emergence of
the lymphatic vasculature (Dumont et al. 1998). Selective
expression of a soluble VEGFR-3-Ig in mouse skin
demonstrated that sequestering VEGFs-C and -D during
embryogenesis prevents formation of lymphatic capillar-
ies as well as regression of previously-formed fetal
lymphatics, without affecting the blood vasculature.
However, lymphatics appeared spontaneously as the mice
got older, suggesting that other factors can compensate
for the loss of VEGF-C or -D in postnatal life (Makinen et
al. 2001a). Further evidence for the importance of these
ligand-receptor interactions for lymphangiogenesis has
come from studies in Chy mice, which carry a sponta-
neous mutation in VEGFR-3 (Karkkainen et al. 2001;
Saaristo et al. 2002) and which display features of
lymphedema, similar to VEGFR-3-Ig transgenic mice.
In summary, in vivo and in vitro studies have
demonstrated that VEGFR-2 signaling regulates angio-
genesis whereas VEGFR-3 signaling mediates lymphan-
giogenesis. However, the role of VEGFR-2 in
lymphangiogenesis and the role of VEGFR-3 in angio-
genesis remain to be established.
Cultured lymphatic endothelial cells
Very few differentially expressed molecules have been
identified to date that distinguish lymphatic from blood
vascular endothelium, and the extent to which the two cell
types are related remains unclear. This scenario has
changed very recently with the first reports which
describe the isolation of lymphatic endothelial cells
(LECs) using specific molecular markers (Kriehuber et
al. 2001; Makinen et al. 2001b; Podgrabinska et al. 2002).
Kriehuber et al. isolated LECs and BECs from adult
human skin by flow cytometry using antibodies to the
lymphatic marker podoplanin (Breiteneder-Geleff et al.
1999; Kriehuber et al. 2001). Makinen et al. employed
antibodies to the extracellular domain of VEGFR-3 to
purify LECs from commercially available human dermal
microvascular endothelial cells (Joukov et al. 1996;
Makinen et al. 2001b). Finally, Podgrabinska et al.
employed antibodies to LYVE-1, a lymphatic specific
receptor for hyaluronan (Banerji et al. 1999), to separate
LECs and BECs from human neonatal foreskin tissue
(Podgrabinska et al. 2002). LECs were characterized by
their homotypic association, selective responsiveness to
VEGF-C in terms of growth, survival and morphogenesis,
and by the differential extracellular matrix requirements.
Microarray analyses revealed important differences be-
tween the two cell types at the molecular level (Petrova et
al. 2002; Podgrabinska et al. 2002). The molecular
signature of LECs appears to reflect their unique func-
tional characteristics. These studies should facilitate the
discovery of novel lymphatic vessel markers, and provide
a basis for the analysis of the molecular mechanisms that
account for the characteristic functions of lymphatic
capillaries.
Lymphatic metastasis: controversies
To enter the lymphatic circulation, tumor cells must
traverse the lymphatic vessel wall. This is believed to
occur at the level of lymphatic capillaries which are
devoid of a continuous basement membrane and peri-
cytes, both of which typically invest blood capillaries. In
addition, while the junctions in blood vessels connect
adjacent endothelial cells over entire cell boundaries, in
lymphatics the junctions are generally more sparse. Based
on these differences, it has been suggested that the entry
Table 1 Experimental models of lymphangiogenesis
Growth factors/receptors
expressed ectopically
Lymphatic marker Animal model References
VEGF-C VEGFR-3 Transgenic expression in mouse skin Jeltsch et al. 1997
LYVE-1 Transgenic expression in mouse pancreas Mandriota et al. 2001
LYVE-1 Viral gene delivery in mouse skin Enholm et al. 2001
LYVE-1, VEGFR-3 Recombinant protein pellets implanted into mouse cornea Kubo et al. 2002
VEGFR-3 Application of recombinant protein to chick CAM Oh et al. 1997
LYVE-1, podoplanin Viral gene delivery or skin-specific transgenic expression
in Chy mice
Karkkainen et al. 2001;
Saaristo et al. 2002
LYVE-1, VEGFR-3 Transfer of naked VEGF-C plasmid in two models of
lymphedema (in the rabbit ear and in mouse skin in the tail)
Yoon et al. 2003
PAL-E/CD31 Recombinant protein injection in a lymphedema model
in the rabbit ear
Szuba et al. 2002
VEGF-C156S LYVE-1, VEGFR-3 Transgenic expression in mouse skin Veikkola et al. 2001
LYVE-1, podoplanin Viral gene delivery or skin-specific transgenic expression
in Chy mice
Karkkainen et al. 2001;
Saaristo et al. 2002
VEGF-D VEGFR-3 Viral gene delivery in rat skin Byzova et al. 2002
LYVE-1, VEGFR-3 Transgenic expression in mouse skin Veikkola et al. 2001
Soluble VEGFR-3 LYVE-1, VEGFR-3 Transgenic expression of VEGFR-3-Ig in mouse skin Makinen et al. 2001a
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of cells into lymphatic vessels is easier than into blood
vessels. This concept, however, still lacks proof, and it
has yet to be demonstrated that the nature of the
lymphatic endothelial junctions facilitates tumor cell
entry. Another dogma has been that the entry of tumor
cells into lymphatics is a passive process. Thus, tumor
cells are believed to be washed into lymphatics along with
interstitial fluid and proteins (Hartveit 1990), or simply to
grow into an adjacent vessel. To date there is no
convincing evidence in the literature which would support
or oppose these concepts. Once tumor cells are in the
lymphatics, they are presumably carried to lymph nodes
by the tide of lymph flow. However, once again nothing is
known about tumor cell behavior within the lymphatic
system. Finally, the prevailing view has been that
lymphatic vessels are absent from tumors and that
lymphangiogenesis does not occur in cancer (Carmeliet
and Jain 2000; Jain and Padera 2002; Leu et al. 2000).
The recent identification of molecular markers of lym-
phatic vessels has made it possible to reexamine these
established views.
Studies using injection techniques have reported the
absence of a functional lymphatic network in tumors, and
this has been ascribed to the solid pressure generated
within tumors as a result of rapidly dividing tumor cells
(Jain 1987; Leu et al. 2000). However, lack of lymphan-
Table 2 Relationship between VEGF-C levels in primary human tumors and lymph node metastases
Tumor type VEGF-C
detection
Relationship
between VEGF-C
and metastases
Comment References
Thyroid carcinoma IHC LN – Tanaka et al. 2002a
RT-PCR LN – Tanaka et al. 2002b
RT-PCR, IHC LN – Bunone et al. 1999
Esophageal SCC IHC LVI, LN Increased MVD Kitadai et al. 2001
Gastric carcinoma IHC LVI, LN – Ishikawa et al. 2003
IHC LVI Poor DFS 5 years Ichikura et al. 2001
RT-PCR, IHC,WB LVI, LN Poor DFS 5 years Yonemura et al. 1999
IHC LVI, none LN – Kabashima et al. 2001
IHC LVI, LN Poor DFS 6 years Takahashi et al. 2002
IHC LVI, LN Increased MVD Amioka et al. 2002
Breast carcinoma IHC None LN Poor DFS 8 years Yang et al. 2002
RT-PCR, IHC LVI Poor DFS 5 years Kinoshita et al. 2001
RT-PCR, IHC None LN – Gunningham et al. 2000
RT-PCR LN – Kurebayashi et al. 1999
IHC None LN Inflammation with increased LVD,
LVI with LN
Schoppmann et al. 2002
Cervical carcinoma RT-PCR LN Poor DFS 5 years Hashimoto et al. 2001
IHC LN Increased MVD, poor DFS 8 years Ueda et al. 2002
Lung carcinoma IHC None LN Correlation VEGF-C level
and VEGFR-3 level in tumor,
poor DFS 5 years
Arinaga et al. 2003
IHC LVI, LN Poor DFS 3 years Kajita et al. 2001
IHC LN – Ohta et al. 2000
RT-PCR LVI – Niki et al. 2000
Mesothelioma RT-PCR 5’-Nase LVI, none LN – Ohta et al. 1999
Pancreatic carcinoma IHC LVI, LN No relationship to DFS 5 years Tang et al. 2001
Endometrial carcinoma IHC LVI, LN Poor DFS 5–10 years Hirai et al. 2001
Ovarian carcinoma IHC LN, peritoneal Poor DFS 10 years Yokoyama et al. 2003
Gallbladder cancer IHC LVI, LN Poor DFS 5 years Nakashima et al. 2003
Neuroblastoma RT-PCR None LN – Komuro et al. 2001
Prostatic carcinoma ISH LN – Tsurusaki et al. 1999
Colorectal carcinoma IHC LVI, LN, liver Poor DFS 5 years Kaio et al. 2003
RT-PCR None LN – George et al. 2001
RT-PCR, IHC LVI, LNs – Akagi et al. 2000
IHC LVI, LN Increased MVD, poor DFS 5 years Furudoi et al. 2002
Head and neck SCC RT-PCR, WB LN – O-Charoenrat et al. 2001
RT-PCR – No relationship between VEGF-C
levels and intratumoral lymphatic
vessel proliferation
Beasley et al. 2002
LVI lymphatic vessel invasion, LN lymph node, none LN no metastases detected in lymph nodes—metastatic status of other organs not
specified, LVD lymphatic vascular density, MVD microvascular density, DFS disease-free survival, SCC squamous cell carcinoma, ISH
in situ hybridization, IHC immunohistochemistry, RT-PCR reverse transcription polymerase chain reaction, WB Western blot, 5’-Nase
5’-nucleotidase/alkaline phosphatase
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giogenesis and/or impairment of fluid and macromolec-
ular transport are not the only possible explanations for
the absence of functional tumor lymphatics. Fluid and
macromolecules travel through tissues according to
hydrostatic and oncotic pressure gradients, following the
pathways of least resistance to transport (Schmid-Schon-
bein 1990). In normal tissues, extracellular matrix fibers
are ideally arranged for directing fluid into lymphatic
vessels (Ryan 1989). In tumors, the extracellular matrix
composition and organization are frequently altered, and
it is possible that fluid channels in tumor stroma do not
direct fluid into tumor lymphatics in an organized
manner. Furthermore, the elevated interstitial fluid pres-
sure in tumors (Jain 1990) may result in steep hydrostatic
pressure gradients at the tumor edge that may primarily
force fluid out of the tumor and not laterally into tumor
lymphatics. Moreover, the conclusion that tumor cells
cannot utilize lymphatic vessels which are undetectable
by lymphangiography, for transport to lymph nodes, is
based on the assumption that the transport of fluid and
cells in tissues and their uptake into the lymphatics is
governed by the same principles. This is unlikely, as cell
migration in tissues is a tightly controlled process
involving a defined set of cell-cell and cell-matrix
interactions. In contrast, the major forces controlling
uptake of fluid and macromolecules into lymphatics are
pressure gradients in tissues (Schmid-Schonbein 1990).
Whether these forces have any effect on cell transport into
the lymphatics remains an open question.
Lymphangiogenic factors and lymphangiogenesis in
human tumors
Expression of lymphangiogenic factors in human tumors
The discovery of the lymphangiogenic factors raised the
question as to whether they are expressed in human
cancers and if so whether this contributes to the ability of
tumors to metastasize. Expression of VEGF-C has indeed
been demonstrated in many human tumors (Salven et al.
1998; Stacker et al. 2002). Although expression of VEGF-
D in human tumors has been less well studied, it has been
detected in melanoma and colorectal carcinoma (Achen et
al. 2001; White et al. 2002).
A number of studies have investigated the relationship
between levels of VEGFs-C and -D and clinicopatholog-
ical features related to the ability of tumors to spread (i.e.,
lymphatic vessel invasion, lymph node involvement and
disease-free survival). With respect to VEGF-C, a signif-
icant correlation between levels in the primary tumor and
lymphatic vessel invasion (LVI) or lymph node metastasis
has been observed in most of the studies (Table 2). Its
expression is often detected preferentially at invasive sites
(Amioka et al. 2002; Furudoi et al. 2002). With respect to
VEGF-D, a correlation with metastasis is less clear
(Table 3). In fact, some studies have suggested that the
expression of VEGF-D in human tumors is reduced
relative to normal tissue (George et al. 2001; O-
Charoenrat et al. 2001). It remains to be seen whether
there is any relationship between VEGF-C and VEGF-D
levels in tumors (Niki et al. 2000; O-Charoenrat et al.
2001). Another avenue thus far unexplored is the role of
VEGFs-C and -D as potential survival factors for tumor
cells in certain cancer types (Fielder et al. 1997; Orpana
and Salven 2002).
Table 3 Relationship between VEGF-D levels in primary human tumors and lymph node metastases
Tumor type VEGF-D
detection
Relationship
between VEGF-D
and metastases
Comment References
Breast carcinoma RT-PCR None LN Inflammatory response Kurebayashi et al. 1999
IHC LN Poor DFS 10 years,
c-erbB-2 overexpression
Nakamura et al. 2003
Gastric carcinoma IHC LVI, LN – Ishikawa et al. 2003
Thyroid carcinoma RT-PCR None LN – Tanaka et al. 2002b
Lung carcinoma RT-PCR LN VEGF-D level in tumor lower than
in normal tissue
Niki et al. 2000
Head and NECK SCC RT-PCR, WB None LN VEGF-D level in tumor lower than
in normal tissue
O-Charoenrat et al. 2001
Ovarian carcinoma IHC LN, peritoneal Poor DFS 10 years Yokoyama et al. 2003
Colorectal carcinoma RT-PCR None LN VEGF-D level in tumor lower than
in normal tissue
George et al. 2001
IHC LN Poor DFS 7 years White et al. 2002
IHC immunohistochemistry, RT-PCR reverse transcription polymerase chain reaction, WB Western blot, LN lymph node, none LN no
metastases detected in lymph nodes—metastatic status of other organs not specified, DFS disease-free survival, SCC squamous cell
carcinoma
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Lymphatic vessels in human tumors
The discovery of lymphatic endothelial markers has for
the first time allowed the unambiguous characterization
of tumor lymphatics and the assessment of lymphangio-
genesis during tumor progression. In several studies, a
strong correlation was found between the presence of
lymphatic markers (e.g., podoplanin, VEGFR-3, LYVE-
1) and lymph node metastases. Tumor cells are frequently
found in juxtatumoral lymphatics and many studies have
reported a strong correlation between LVI and lymph
node involvement (Table 4). LVI has long been consid-
ered to be an important prognostic indicator in cancer.
However, in these studies, lymphatic vessels were
identified by morphological criteria alone; recent studies
using molecular markers are in agreement with this
notion. Intratumoral lymphatics have so far been observed
only in human head and neck cancers and in melanoma
(Beasley et al. 2002; Dadras et al. 2003). On the contrary,
enlarged, dilated lymphatic vessels, in which endothelial
proliferation is often observed, are very frequently present
in peritumoral areas of many tumor types (Beasley et al.
2002; Niki et al. 2001; Padera et al. 2002; Straume et al.
2003).
It is not known to what extent tumor cell-secreted
factors are directly responsible for the formation of the
large lymphatic vessels that are detected around human
tumors. Inflammatory cells could, for example, also
contribute to lymphatic enlargement and lymphangiogen-
esis. A recent study has demonstrated that in breast
cancer, tumor-associated macrophages express VEGFs-C
and -D, thereby indicating an additional source of
lymphangiogenic factors (Schoppmann et al. 2002).
VEGF-C is also chemotactic for macrophages (Skobe et
al. 2001b) and is readily induced by proinflammatory
cytokines (Narko et al. 1999). In this regard, a significant
correlation between the tumor inflammatory response and
lymphangiogenic factor expression has been observed in
breast and cervical cancer (Kurebayashi et al. 1999;
Schoppmann et al. 2002).
With respect to lymphatic vessel density (LVD), a
correlation exists between the number of tumor-associat-
ed lymphatics and the presence of lymph node metastases
for a given tumor type (Table 4). However, a comparison
of tumor-associated LVD with LVD of the tissue in which
the tumor arose has only been undertaken in a limited
number of studies. In a single study of colorectal
carcinoma, LVD was increased in tumors relative to
normal colonic mucosa (White et al. 2002). In two other
studies on cervical and gastric cancers, although there was
a trend towards an increase in tumor associated LVD, this
did not reach statistical significance (Schoppmann et al.
2002; Yonemura et al. 2001). A melanoma study reported
that LVD associated with tumors was comparable to LVD
in normal skin (de Waal et al. 1997).
Existing lymphatic vessels in the surrounding tissue
provide a readily accessible avenue for tumor cell
dissemination. Tumor spread via the lymphatic vascular
bed may therefore be facilitated by the high intrinsic
lymphatic density in the tissue in which the tumor arises.
Although preexisting peritumoral lymphatics are likely to
be sufficient for tumor spread, recruitment of lymphatic
vessels into the close proximity of a tumor may increase
the propensity of the tumor to metastasize. Therefore,
increased lymphatic vessel density as well as the presence
of intratumoral lymphatics should be regarded as an
additional pathway rather than a necessity for metastasis.
Whereas a relative increase in LVD has been correlated
with a more metastatic phenotype, future studies are
required to determine whether intratumoral lymphatics
are restricted only to certain cancer types and whether
their presence in tumors has prognostic significance.
Table 4 Relationship between lymphatic density in primary human tumors and lymph node metastases
Tumor type Lymphatics
detection
Relation with
metastases
Comment References
Lung carcinoma IHC (VEGFR-3) LN Ki67 in lymphatic vessels Niki et al. 2001
Endometrial carcinoma IHC (VEGFR-3) LN Poor DFS 5 years Yokoyama et al. 2000
Gastric carcinoma IHC (VEGFR-3) LVI, LN Correlation VEGF-C level
and VEGFR-3 level in tumor
Yonemura et al. 2001
Cutaneous melanoma IHC (LYVE-1,
podoplanin)
None LN Ki67 in lymphatic vessels, peritumoral
LVD with poor DFS 5 years but not
intratumoral LVD
Straume et al. 2003
Tongue SCC IHC (VEGFR-3) LN – Okamoto et al. 2002
Head and neck SCC IHC
(LYVE-1/CD34)
LN (only in
oropharyngeal
carcinoma)
Intratumoral lymphatic vessels Beasley et al. 2002
Cervical carcinoma IHC (podoplanin) LN LVI Schoppmann et al. 2001b
IHC (podoplanin) LN LVI with poor DFS 10 years Birner et al. 2001
Breast carcinoma IHC (VEGFR-3) LN – Nathanson et al. 2000
IHC (podoplanin) LN LVI with LN but not LVD with LN Schoppmann et al. 2001a
LVI lymphatic vessel invasion, LN lymph node, none LN no metastases detected in lymph nodes—metastatic status of other organs not
specified, LVD lymphatic vessel density, DFS disease-free survival, SCC squamous cell carcinoma, IHC immunohistochemistry, n.d. not
determined
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Finally, the relative importance of preexisting versus
newly formed lymphatic vessels to lymphogenous metas-
tasis remains poorly understood.
Experimental models implicating lymphangiogenesis in
tumor spread
In addition to clinicopathological studies which have
provided a correlation between VEGF-C expression in
primary tumors and tumor spread via lymphatics, several
recent experimental studies have provided direct evidence
for the importance of VEGF-C in tumor lymphangiogen-
esis and metastasis (Table 5).
In our own studies, transgenic mouse lines were
established in which VEGF-C expression, driven by the
rat insulin promoter (Rip), was targeted to beta cells of the
endocrine pancreas. Transgenic RipVEGF-C mice devel-
oped an extensive network of lymphatics around islets of
Langerhans, as shown by a number of criteria including
staining with the lymphatic endothelial cell-specific
marker, LYVE-1 (Mandriota et al. 2001). As a model of
tumor progression in the same tissue, Rip1Tag2 mice
(Hanahan 1985) were employed. In these mice, expres-
sion of the SV40 oncogene is driven in islet beta cells by
the rat insulin promoter. These mice predictably and
reproducibly develop pancreatic beta-cell tumors which
are not metastatic. When RipVEGF-C and Rip1Tag2
mice were crossed, it was found that double transgenic
mice formed tumors surrounded by well-developed lym-
phatics, and that this was accompanied by the formation
of metastases in regional pancreatic lymph nodes (Man-
driota et al. 2001). Of importance was the finding that in
the same model, tumor cells overexpressing VEGF-A
promoted angiogenesis and tumor growth, but did not
promote either lymphangiogenesis or the formation of
lymph node metastasis (Gannon et al. 2002).
Skobe et al. demonstrated that overexpression of
VEGF-C in MDA-MB-435 human breast cancer cells
increased the incidence of metastases to regional lymph
nodes following orthotopic transplantation of the cells
into immunocompromised mice (Skobe et al. 2001b).
Interestingly, this study showed that VEGF-C-induced
lymphangiogenesis not only correlated with lymph node
metastasis, but also with lung metastases (Skobe et al.
2001b). Induction of tumor-associated lymphangiogenesis
by VEGF-C and a subsequent increase in metastases has
also been reported using MCF-7 human breast cancer
cells (Mattila et al. 2002), in a mouse sarcoma model (Leu
et al. 2000; Padera et al. 2002) and in an immunocom-
petent rat model using the weakly metastatic NM-081 rat
mammary carcinoma cell line overexpressing VEGF-C-
C152S (Krishnan et al. 2003). Stacker et al. demonstrated
a role for VEGF-D in lymphatic-dependent tumor cell
dissemination using a 293EBNA xenotransplantation
model (Stacker et al. 2001). Importantly, when tumor
cells overexpressing VEGF-A were assessed in the same
setting, angiogenesis and tumor growth were increased
with no effect on either lymphangiogenesis or the
formation of lymph node metastases. Targeting of
VEGF-C/VEGFR-3 in two mouse and in one rat tumor
model expressing high levels of VEGF-C resulted in
decreased lymphangiogenesis and reduction of lymph
node metastases (He et al. 2002; Karpanen et al. 2001;
Krishnan et al. 2003).
Conclusion and perspectives
As with the blood vascular system, tumor cell dissemi-
nation via lymphatics requires their intravasation into
lymphatic capillaries. Recent studies on human and
mouse tumors have convincingly demonstrated the
importance of VEGF-C in lymphogenous metastasis.
Although VEGF-C may increase the propensity of tumors
to metastasize simply by increasing tumor cell access to
lymphatic vessels via induction of lymphangiogenesis, it
is equally conceivable that lymphatic endothelial cells
and tumor cells enter into a reciprocal dialogue. VEGF-C
may alter the function of preexisting lymphatics which
may then become actively involved in tumor cell
chemotaxis, lymphatic intravasation and dissemination.
For example, chemokines may be the mediators of
directional tumor cell migration. VEGF-C may also alter
adhesion molecule expression in lymphatic endothelial
cells.
Understanding the molecular and cellular mechanisms
of metastasis is essential for the development of new
forms of cancer therapy. In preclinical studies, molecules
which have been shown to be effective in inhibiting tumor
lymphangiogenesis and lymph node metastasis include a
soluble VEGFR-3-IgG fusion protein and neutralizing
anti-VEGF-D antibodies. Furthermore, indolinones have
been synthesized and characterized that differentially
block VEGF-C- and -D-induced VEGFR-3 kinase activity
but not that of VEGFR-2 (Kirkin et al. 2001). These tools
provide a glimpse of what could potentially be a novel
therapeutic opportunity for preventing or halting tumor
cell dissemination and the formation of metastasis.
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